Entering text into the input field will update the search result below

The First Look At Checkmate Pharmaceuticals


  • Today, we become the first Seeking Alpha contributor to put Checkmate Pharmaceuticals in the spotlight since its IPO last summer.
  • The company is focused on harnessing the power of one’s immune system to fight cancer.
  • A full analysis on Checkmate Pharmaceuticals follows in the paragraphs below.
  • I do much more than just articles at The Busted IPO Forum: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »

Research into Diabetes
Photo by SolStock/E+ via Getty Images

"Cure the symptoms, cure the disease."― Michael Critchton

Today, we take a look at a 'Tier 4' developmental concern focusing on new treatments for cancer. The firm came public in August, and has yet to

Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum. Try a free 2-week trial today by clicking on our logo below!

This article was written by

Busted IPO Forum profile picture

The Busted IPO Forum founded by Bret Jensen, focuses on stocks that have been public for 18 months to six years that are significantly under their offering price, AKA Busted IPOs.  Many times, after the initial analyst hyperbole has died and insider stock lockups have expired, these same companies can be had for .30 to .50 cents on the dollar from when the shares went public. 

• • •

Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.

• • •

Learn more about Bret Jensen's Marketplace offerings:

The Insiders Forum | The Biotech Forum | Busted IPO Forum

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (2)

Bret Jensen profile picture
Checkmate Pharmaceuticals (NASDAQ:CMPI) presents new translational data from its Phase 1b trial of vidutolimod (CMP-001) in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma.
Response rates to vidutolimod in combination with pembrolizumab were similar across baseline patient characteristics including BRAF mutation, LDH level, number of prior systemic cancer treatments, best response to prior PD-1 blockade therapy, and prior ipilimumab.
All patients showed the expected rapid induction of anti-Qb antibodies to the virus-like particle, which facilitate the pharmacodynamic response to vidutolimod, and the antibody titers were not associated with clinical response.
Clinical activity of vidutolimod + pembrolizumab was associated with serum CXCL10 induction magnitude, induction of an inflammatory gene expression profile, and CD8+ T cells in injected and noninjected tumors.
The data was presented at AACR 2021.
Thank you for this article on CMPI. I like their science.

I remember that CMPI went public about the same time as PAND, and so their lockup expirations were close in time. I waited until the lockup exp to buy the names. PAND did not go down at that time, which I took as a buy signal and started buying. Unfortunately, I didn't get a chance to buy much. I was waiting for a pull-back, which, of course, never came.

I have started to buy CMPI. They are down due to general BT blues.
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.